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1. INTRODUCTION AND OBJECTIVES 
The need for an ever more perfect correction of both 
congenital and acquired refractive defects has come more and more 
to the foreground in the past century. Out of these tendencies, one 
of the most developing segments is the refractive laser eye surgery 
method done with an excimer laser. These surgical interventions 
ŵodifǇ the eǇe’s foĐusiŶg poǁer aŶd thus the Ŷeed for ĐorreĐtioŶ 
by changing the refractive power of the cornea. The first excimer 
lasers, working prinĐiple of ǁhiĐh is the saŵe as todaǇ’s lasers’, 
started to appear by the end of the 1980s. However, despite the 
significant development of technology, even nowadays, after the 
now routine excimer laser treatments, adverse reactions causing 
impaired vision or the reduction of visual acuity may appear. 
Recently, the most frequent type of refractive excimer 
laser treatments is photorefractive keratectomy (PRK) the laser-
assisted in situ keratomileusis (LASIK), the laser-assisted epithelial 
keratomileusis (LASEK) and the epithelial laser in-situ keratomileusis 
(Epi-LASIK). 
Based on our current knowledge, corneal wound healing 
processes are controlled by two big systems with the help of 
activators and inhibitors. One of the systems is the plasminogen 
activator-plasmin system, whose significance lies in degradation and 
the removal of the damaged extracellular matrix. The other system 
is responsible for the creation of the newly synthesized collagen 
fibrils in place of the damaged collagen structures with the help of 
activated keratocytes. The correct operation of the above 
mentioned systems is inevitable for re-epithelization, i.e. for proper 
wound healing. The disturbance in the equilibrium of the two 
systems can result in protracted, pathological wound healing, in 
serious cases, corneal ulcer. 
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In 2000, Csutak et al. reported on the activity pattern 
changes of urokinase plasminogen activators (uPA) in human tears 
following PRK treatments. They observed a reduction of the uPA 
activity in case of normal wound healing right after laser treatment, 
then an increase above the preoperative values on the 
postoperative third day and their return to the level of preoperative 
values on the postoperative fifth day. Conversely, in case of the 
development of corneal stromal haze, the increase of uPA activity 
did not take place on the postoperative third day. 
The connection between the change of plasminogen 
activators and the development of haze was examined even after 
the photorefractive laser treatment of pregnant rabbits (Csutak et 
al., 2004). During their animal experiments, the activity pattern of 
plasminogen activators in the tear samples treated with serine 
protease inhibitor (aprotinin, Gordox, Richter Gedeon Rt., Budapest, 
HuŶgarǇͿ, as ǁell as iŶ pregŶaŶt aŶiŵals’ tear saŵples that were 
not treated with aprotinin matched with the activity pattern 
measured in the tear samples of patients that had corneal haze and 
were previously treated with PRK. In these cases, uPA growth in 
tear was not detectable on the postoperative third day. During the 
examinations, haze developed in case of seven out of eight 
pregnant rabbits treated with PRK. When the eyes of pregnant 
rabbits were treated with uPA, none of them had stromal haze 
developed. This result that is, most of pregnant rabbits who were 
cured from corneal haze following the excimer laser treatment 
indicated the possibility of a relationship between pregnancy and 
pathological corneal wound healing in case of human pregnancies 
too. Therefore, we started to examine the change of plasminogen 
activator inhibitors level in human pregnant tears. 
In the human body, the operation of plasminogen 
activators is blocked by the plasminogen activator inhibitors, which 
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have two types, namely, PAI-1 and PAI-2. The plasminogen activator 
cascade plays a role in several physiological and pathological 
processes, e.g. fibrinolysis, wound healing, inflammatory processes, 
angiogenesis, ovulation, neuroplasticity as well as the growth, 
invasion and metastasis of malignant tumours. 
The accumulation of inhibitors in blood can lead to 
thrombosis due to their antifibrinolytic impact. Normal pregnancy is 
accompanied by the reduction of fibrinolytic activity and the growth 
of PAIs concentration in blood, thus creating a 
hypercoagulable state. Both the coagulation and fibrinolysis 
strengthens over time during pregnancy, especially in the 2
nd
 and 3
rd
 
trimester. The PAI-1 and in particular the PAI-2 concentration as an 
antifibrinolytic factor are continuously growing during pregnancy, 
already in the early periods and it creates a complex both with the 
tPA and uPA, thus less plasminogen transforms into active 
plasminogen and the fibrinolytic activity reduces. However, the full 
fibrinolytic activity remains constant in pregnant women in spite of 
the significant change in the tPA, uPA, PAI-1 and PAI-2 levels. In 
possession of the above mentioned results, we started to examine 
the changes in level of plasminogen activator inhibitor-2 following 
the refractive laser surgery operations (PRK, LASIK), and also in 
pregnant women in order to get closer to a more accurate 
understanding of the background of biochemical processes during 
corneal wound healing. 
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Objectives:  
1. Our first goal was to examine the change in level of 
plasminogen activator inhibitor in tears after 
photorefractive eye treatments.  
2. The second aim was to study the change of plasminogen 
activator inhibitor level and make comparisons following 
photorefractive keratectomy and laser in situ 
keratomileusis.  
3. Our additional objective was to analyse the change of the 
plasminogen activator inhibitor-2 level in the tear samples 
of pregnant women. 
4. Finally, we examined the change of the plasminogen 
activator inhibitor-2 level in blood of pregnant women 
comparing the results to the values taken from the tear 
samples.  
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2. LITERATURE REVIEW 
2.1. The plasminogen activator-plasmin system 
In mammals, the plasminogen activator system is 
controlled on numerous levels. One of the most important of these 
is the activity blocking of plasminogen activators by their inhibitors. 
Plasminogen activators are specific serine proteases that are 
responsible for the breaking of bond between the plasminogen 
ArgЊЋЅ-ValЊЋІ in the human body, thus for transforming inactive 
plasminogen into active ones, thereby catalysing the extracellular 
proteolysis. The two types of plasminogen activators are the tissue-
type plasminogen activator (tPA) and the urokinase-type 
plasminogen activator (uPA). 
Primarily, tPA plays a role in the fibrinolytic activity of 
blood, for which fibrin cofactor is necessary, and for its production 
and secretion into blood vascular endothelial cells are responsible 
first and foremost. The plasminogen activator inhibitor-1 is the 
most important participant in its blocking. 
The major role of uPA is in extracellular proteolysis, and 
most probably plays an active part in the creation of metastasis and 
invasion in tumours. There is no need for fibrin cofactor for its 
operation. The uPA is synthesized by endothelial cells, macrophages 
and different types of leukocytes. The uPA is a tear component that 
is produced by conjunctival and corneal epithelial cells. uPA activity 
increases with the appearance of several corneal illnesses, e.g. 
ulcer, and even after the refractive laser treatments accompanying 
corneal wound, which refers to the fact that the fibrinolytic system 
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plaǇs a role iŶ the eǇe’s ǁouŶd healiŶg proĐesses. “eǀeral studies 
dealing with the re-epithelization of corneal wound reported about 
the existence of uPA and its receptors in keratinocytes. The 
plasminogen activator inhibitor-2 plays the most significant role in 
its blocking. 
2.2. Plasminogen activators and the change of their inhibitors in 
corneal wound healing 
We can witness the decrease in corneal transparency in 
case of scarring after injuries and surgeries, in case of corneal 
degeneration or dystrophy, several inflammatory diseases or as a 
side effect of certain medications (e.g. epinephrine). Occasionally, 
as we reported it previously, it can happen that corneal 
pigmentation develops in the corneal stroma following the 
phagocytosis of the pigment granules by endothelial cells in the 
anterior chamber and their traŶsportatioŶ through the DesĐeŵet’s 
membrane. In these cases, we can see the incorporated pigment 
granules in the macrophages that migrated from the limbal areas to 
the corneal stroma and in some keratocytes. The slow clearance of 
pigment-filled macrophages starts in the limbus and continues its 
way towards the centre, whereas the keratocytes containing 
pigments remain in the stroma, thus causing the decrease in corneal 
transparency, and, ultimately, the deterioration of visual acuity. 
Froŵ todaǇ’s perspeĐtiǀe, ĐorŶeal ǁouŶd healiŶg is 
controlled by two big systems with the help of activators and 
inhibitors. One of the systems is the plasminogen activator-plasmin 
system, whose significance lies in in degradation and in covering the 
damaged extracellular matrix. The other system is that of activated 
keratocytes, that is responsible for the creation of the matrix of 
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newly synthesized collagen fibrils in place of damaged collagen 
structures and of glycosaminoglycan surrounding collagen fibrils. 
The proper operation of the above mentioned systems is inevitable 
for re-epithelization. The imbalance in the two systems can cause 
protracted, pathological wound healing, in serious cases corneal 
ulcer creation. 
The corneal, conjunctival and lacrimal gland cells are all 
capable of producing plasminogen activators. The plasminogen 
activator found in the cornea is of urokinase-type, whereas the 
lacrimal gland can only produce the tissue-type plasminogen 
activator. Both types of activators can be detected in the 
conjunctiva. In these tissues, uPA is probably originating from the 
epithelial cells of cornea and conjunctiva, while tPA is produced by 
the vascular endothelial cells of the conjunctiva. We know that 
normal tear contains protease inhibitors in a very small 
concentration, however, in tears of people suffering in certain 
ophthalmological diseases (e.g. corneal ulcer, vernal kerato-
conjunctivitis) the inhibitor concentration significantly grows and 
returns back to the normal level only after the healing process.  
In normal tears, uPA activity is very low, while tPA activity 
is practically non-detectable. PAI-1 has not been detected in normal 
tear so far, therefore we assume that PAI-2 plays a role in the 
blocking of uPA produced by the epithelial cells of the anterior 
segment of the eye. 
In case of the damaged epithelial cells in the cornea and 
conjunctiva (e.g. inflammation processes, certain surgical 
interventions), larger quantity of uPA is identified in tears. uPA is 
capable of activating the plasminogen in tears, transforming it into 
plasmin, which process is set back by inhibitors. 
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In case the created plasmin does not get activated, it can 
set in motion several processes on the anterior segment of the eye 
(e.g. it can lead to ulcer due to the dissimilation of the collagen 
constituting the basis of the cornea and of the collagenase activated 
with the help of the plasminogen activator-plasmin system). In 
pathological conditions, affecting the anterior segment of the eye 
(e.g. conjunctivitis, keratitis, etc.), the permeability of conjunctival 
vessels usually intensifies, thereby proenzyme forms of proteinases 
and proteinase inhibitors get into the tear. If the damage reaches 
the level when the uPA activity depletes the inhibitors that get into 
the tears with transudation, tears can become proteolytically active 
due to the continuous production of plasmin. The great amount of 
plasmin activates the pro-collagenase into collagenase, as a result of 
which, corneal ulcer can also develop. However, the not too 
excessive activation of the plasminogen activator-plasmin system is 
inevitable during the wound healing processes. Their activation 
plays a significant role in the disposal of cell and tissue debris, as 
well as in repairing the damaged collagen and extracellular matrix. 
In the light of the above, we can say that the plasminogen 
activator-plasmin system can play a key role in the degrading 
dissimilation of protein during the pathological processes in the 
anterior segment of the eye, in a similar way to other extracellular 
proteolytic processes such as malignant cell invasion. It seems that 
the uPA plasminogen-plasmin system plays a crucial role in the 
wound healing processes, including the pathogenesis of epithelial 
defects. Although an exact mechanism, which would be the basis of 
corneal wound complications following surgical interventions, is not 
known, we can assume that individual variations in corneal wound 
healing are also key players in the refractive regression following 
surgical interventions and in the development of corneal stromal 
haze.  
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The low activity of the plasminogen activator-plasmin 
system can lead to protracted wound healing, or even to chronic 
epithelial erosion.  
2.3. The change of the plasminogen activator/activator inhibitor 
system during pregnancy 
The work of plasminogen activators is held back by the plasminogen 
activator inhibitors, which has two types, PAI-1 and PAI-2. The 
plasminogen activator inhibitor-1 is produced by the vascular 
smooth muscle cells, thrombocytes and hepatic cells. The 
plasminogen activator inhibitor-2 is primarily produced by 
trophoblasts, and they have an important part in the blocking of 
uPA during pregnancy. The multiplication of fibrinolytic inhibitors 
can lead to thrombosis. Normal pregnancy is accompanied by the 
reduction of fibrinolytic activity and by the increase of PAIs 
concentration in the blood, thus creating a hypercoagulable state. 
Both coagulation and fibrinolysis strengthen with the development 
of pregnancy, especially in the 2
nd
 and 3
rd
 trimester. This 
hypercoagulable state protects women from fatal bleeding during 
child-birth, but also predisposes them to thromboembolic diseases. 
During pregnancy, the primary fibrinolytic components, the amount 
of tPA and uPA temporarily decreases in the first and second 
trimester, whereas, in the third trimester, the concentration of uPA 
significantly grows compared to the level of concentration before 
pregnancy. The seriously reduced fibrinolytic activity can cause pre-
eclampsia, placental abruption and intrauterine growth restriction 
in pregnancy. PAI-1 and mainly the concentration of PAI-2, as an 
antifibrinolytic factor is constantly growing even starting from early 
pregnancy and creates a complex both with tPA and uPA, and 
therefore less plasminogen transforms into active plasmin, and the 
fibrinolytic activity decreases. Up until now, it is still not clarified 
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whether the plasminogen activator level drop measured in the first 
two trimesters is the result of the reduced synthesis, the increased 
͞turŶoǀer͟ or the Đoŵpleǆes Đreated ǁith iŶhiďitors, ďut the 
biologically active tPA and uPA levels measurably decrease. In the 
32
nd
 week of pregnancy, increased amount of uPA can be measured, 
which suggests that in this period of pregnancy the increased 
synthesis of activator is formed. The full fibrinolytic activity remains 
persistent in spite of the significant change of the tPA, uPA, PAI-1 
and PAI-2 levels. 
The coagulation activity, anticoagulation activity, the fibrinolytic and 
antifibrinolytic activity increase during normal pregnancy, but these 
activities are balanced. This balance and change is necessary so that 
the hemodynamics in the umbilical artery and in the uterine artery 
become baby-friendly (high stream, low resistance) with the 
development of pregnancy. 
In view of the findings described above, we started to 
analyse the changes of the plasminogen activator-plasmin system in 
healthy, human pregnancies, of which, as we know, there is no 
available information in the literature. Furthermore, we studied the 
PAI level changes during LASIK and PRK to get closer to a more 
accurate understanding of the background of biochemical processes 
during corneal wound healing based on the results obtained. 
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3. PATIENTS AND METHODS 
3.1.1. Patients undergoing excimer laser treatment  
In accordance with the content of the Helsinki Declaration, 
following the authorized signature of ethical permit by the local 
Ethical Committee, the study of corneal wound healing was 
performed on 46 eyes of 38 patients with PRK (8 patients with both 
eyes), and 13 eyes of 8 patients (5 patients with both eyes) with 
LASIK treatment. In the case of PRK, the average value of the pre-
surgical refractive errors was -4,11 (±2,22) D, while during LASIK, 
this value was -5,13 (±1,89) D. The preoperative refractive error in 
case of patients undergoing PRK and LASIK treatments, examining 
them with the two-sample t-test there was no significant difference 
(p=0,152). For those, who were taken tear samples from both eyes, 
the difference of the refractive error between the eyes was 1,2 
(±1,4) D. Using F-test, we compared the refractive error of those 
patients, whose both eyes underwent laser treatment, with those, 
whom only had one eye treated, but significant difference was not 
detectable in this case either (p=0,17). The average age of patients 
undergoing PRK was 25 (±5), whereas that of patients treated with 
LASIK was 28 (±9). We have not found any significant difference 
(p=0,535) among the average ages using t-test.  
3.2. Laser treatments 
The correction of refractive errors was done with excimer laser 
treatment together with local anaesthesia (193 nm InproArF -
excimer laser, Intraocular Prosthetic GmbH, Norderstedt, Germany), 
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which was performed by the same ophthalmologist in each and 
every case. 
In the case of PRK, we used keratome blade to remove the epithelial 
cell layer of the cornea, we applied the Hoffer trephine as a marker, 
the diameter of which in case of spherical correction was 6,0-6,5 
mm, while in case of astigmatic correction it was 7,5- 8,0 mm. We 
carefully scratched off the epithelium progressing from the 
periphery of the cornea towards the centre, so that we preferably 
could avoid injuring the Bowman’s ŵembrane. We used sterile 
tampon gauze to remove the epithelial rests. 
In the case of LASIK, we used the Hansatome Model HT 230 
microkeratome (Chiron) to create the corneal flap. The flap was 180 
µm thick in every eye, when the corneal thickness after the 
refractive correction (following the deduction of the flap thickness) 
remained at least 250 µm thick. 
If the corneal thickness was thinner, we reduced the flap thickness 
to 160 µm. The diameter of the ablative zone was 6,5 mm. 
Comparing the depth of the ablative zones, we did not find any 
significant difference between the two surgery types (In the case of 
PRK 48±20 µm; LASIK 59±13 µm, p=0,074).  
3.2.1. Pre–and postoperative treatment, control examinations, 
evaluation of the corneal stromal haze in the case of patients 
undergoing laser treatment  
Before laser surgeries, we gave the patients local 
anaesthetic drops (Humacain Oxybuprocaine hydrochloride, TEVA 
Pharmaceuticals). After the surgery, we applied Ciloxan antibiotic 
eye drops (Ciprofloxacin HCL 0.3%, Alcon) in every hour on the first 
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day following the surgery, and we continued it for five more days 
five times a day. Five days later, we instilled steroid filled Flucon 
(Fluorometholone 0.1%, Alcon) and Tears Naturale 
(Dextran/Hydroxypropyl Methylcellulose, Alcon) artificial tears. This 
treatment was repeated five times a day in the first month, 4 times 
a day in the second month, and three times/day in the third month. 
Every patient went through control examinations one and three 
months after the laser surgery. 
We performed the tear sampling based on the protocol in 
the case of preoperative and immediate postoperative state, 
following both types of laser treatment, as well as in the case of PRK 
on the 3
rd
 and 5
th
 day, while in case of LASIK it was performed on 
the first day following the surgery in accordance with the 
conventional control dates. The evaluation of the corneal stromal 
haze in this study was performed based oŶ the HaŶŶa’s stadiuŵ 
classification. 
3.3.1. Pregnant patients 
In our further analysis, we collected tear and blood samples from 32 
pregnant patients four times in the 8
th
 and 36
th
 week of their 
pregnancy, and within one week after them giving birth according 
to the content of the Helsinki Declaration, following the authorized 
signature of ethical permit by the local Ethical Committee. The 
sampling was done at the ambulance of the Obstetrics and 
Gynaecology Clinics, Medical and Health Science Centre of the 
University of Debrecen. 
The age of the pregnant patients was between 19-33, the average 
being 27,42 (±4,13) years old. Each pregnancy went through 
normally without any pre- or postnatal adverse reaction. Our 
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pregŶaŶt patieŶts’ aŶaŵŶesis, there oĐĐurred Ŷo heŵatopoietiĐ 
system or other kind of disease, medication. Two pregnant women 
were wearing contact lenses during pregnancy. 
3.3.2. Control examination of pregnant patients 
We categorized the ages of our pregnant patients as follows: 8-13, 
16, 23-26 and 34-36 weeks, as well as the first week after child-
birth. The control examination of pregnant patients was performed 
in accordance with this classification. 
3.4. Tear sampling of patients undergoing laser treatment and 
pregnant women  
We collected the tear samples into glass capillary tubes 
immediately before and after the laser surgery and also on the 
conventional control days without excitation. Tear sampling of 
pregnant women during the above mentioned controls was done in 
the same way as that of patients undergoing laser treatment. In 
every case, the sampling was performed before applying eye drops 
(a minimum of two hours after using preventing drops), using glass 
capillaries (length: 10 mm, diameter: 1 mm), and it was taken from 
the pre-corneal tear film close to the lower eyelid margin line taking 
care to avoid touching the conjunctiva. We recorded the duration of 
sampling and also the amount of tear sample. The secretion rate in 
the case of laser treated patients was 5-15 µl/min, in the case of 
pregnant women it was 5-18 µl/min. Every sample was centrifuged 
(at 1800 rpm) right after sampling, and the supernatant was stored 
at -80 °C until use. They were defrosted only once directly before 
measurements. Regarding our control samples, the collection of 
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samples was performed at the same time and in the same method 
as that of the sampling of the eye undergoing operation. 
3.4. Blood collection from pregnant women 
During our analysis, we collected 4 ml blood from the ulnar 
veins from 25 pregnant women (87 samples), according to the 
above mentioned control dates, and also within a week after child-
birth to diagnose PAI-2 and from 10 pregnant women (20 samples) 
to detect PAI-1. In addition, we took blood sample during controls 
from 17 pregnant women (51 samples) to identify the levels of 
progesterone and estradiol. The collecting was done in 
anticoagulant (0,5 ml, 0,105 M Trisodium Citrate) tubes that were 
put on ice after taking the samples. After centrifugation (1800 rpm, 
10 min), following the separation of plasma, we froze it to -80°C and 
only defrosted it at the time of measuring. 
3.5. The identification of plasminogen activator inhibitor 
With the help of enzyme-linked immunosorbent assay 
(Imubind Elisa, American Diagnostica GmbH, Pfungstadt, Germany), 
we determined the PAI-2 level of both tear and blood in accordance 
ǁith the ŵaŶufaĐturer’s iŶstruĐtioŶs. We used aŶ enzyme-linked 
immunosorbent assay (Imubind ELISA) to measure the PAI-1 and 
PAI-2, with the help of which we can define the human PAI-1 and 
PAI-2 in human biological liquids. 
In the case of PAI-2, the lower limit of detection was 1 
ng/ml in case of patients undergoing excimer laser. The free PAI-2 
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and PAI-2/upA complex can be detected with the same sensitivity. 
The Imubind PAI-2 ELISA uses polyclonal antibody against the 
human PAI-2 antibody. We incubated the samples in precoated-
microtest cell and adding the antibodies to them, we detected 
bound PAI-2 molecules. The added Streptavidin-Horseradish 
Peroxidase covers entirely the production of antibody-enzyme 
complexes in this case too. The addition of perborate/ϯ,ϯ’,5,5’-
Tetramethylbenzidine substrate, and its final reaction with the 
Horseradish Peroxidase results in a blue solution. The sensitivity can 
be increased with sulphuric acid solution that stops the process and 
converts the solution into yellow colour. We can measure the PAI-2 
level in a quantitative way on 450 nm, and we can also compare the 
results obtained with the results of a standard diagram. In the case 
of patients undergoing laser treatment, we identified PAI-2 using 
146 tear samples from the PRK treatment of 46 eyes, and 35 tear 
samples from the LASIK treatment of 13 eyes.  Furthermore, 56 tear 
samples of 19 pregnant women and 87 blood samples of 25 
pregnant women were used to define the PAI-2 levels (the lower 
limit of detection was 100 pg/ml). 
The identification of PAI-1 was also done with the help of 
enzyme immunoassay (Imubind Elisa, American Diagnostica GmbH, 
PfuŶgstadt, GerŵaŶǇͿ iŶ aĐĐordaŶĐe ǁith the ŵaŶufaĐturer’s 
instructions. During Imubind PAI-1 ELISA, we used a murine anti-
human PAI-1 antibody. Afterwards, we made detection of PAI-1 like 
we did it in case of PAI-2. The PAI-1 level of tear remained under the 
assay detection level among patients undergoing excimer laser (1 
ng/ml) and among pregnant women as well. The free and complex 
PAI can be identified with the same sensitivity; the assay is 
insensitive to PAI-2. 
We measured the PAI-1 levels in the tear samples of 61 
patients undergoing PRK treatment, and also in 45 tear samples of 
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13 pregnant women and in 20 blood samples of 10 pregnant 
women. The free and complex inhibitors were identified with the 
same sensitivity by ELISA. During our measurements, not any 
sample PAI value was over the lower level of detectability, therefore 
we did not perform the measuring of PAI-1 in the tear samples of 
patients treated with LASIK. 
DuriŶg the aŶalǇsis of pregŶaŶt ǁoŵeŶ’s tear saŵples, as a 
comparison, we used PAI-1 (in 64 tear samples) and PAI-2 (in 37 
tear samples) levels in tears of equal age for negative control, which 
we extracted from the analysis of tear samples gathered from 
pregnant women undergoing corneal laser treatment. 
3.6. The identification of Estradiol and Progesterone 
Out of the total number of our pregnant patients, we identified the 
estradiol and progesterone levels in 51 blood samples of 17 women. 
The ideŶtifiĐatioŶ ǁas doŶe ǁith the help of ͞eleĐtro-
ĐheŵiluŵiŶesĐeŶĐe iŵŵuŶoassaǇ͟ ;ECLIA, Elecsys Estradiol CalSet 
II. and Elecsys Progesterone II. CalSet, Roche Diagnostics GmbH, 
Mannheim, Germany) in accordance with the manufacturer’s 
instructions. 
3.7. Statistical methods  
For the study of PAI changes during the wound healing 
process after excimer laser treatment and in the different periods of 
pregnancy, we performed a standard statistical analysis. For the 
comparison of the results of PRK and LASIK PAI-2, as well as the 
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comparison of the PAI-2, estrogen and estradiol levels measured in 
pregŶaŶt ǁoŵeŶ’s ďlood aŶd tear, ǁe used tǁo-sample t-test in the 
case of samples taken in different periods. We considered the 
difference as significant when it was p<0,05, and we mentioned 
explicit significance when the value there was a p<0,01 value. 
4. RESULTS 
4.1. The amount of PAI in human tear following refractive laser 
treatment  
We identified the PAI-1 ELISA in 61 PRK tear samples, 
which affected the samples of all four dates. None of the PAI-1 
values reached the lower level of detectability.  
We performed the identification of PAI-2 ELISA on 146 PRK 
and 35 LASIK tear samples. The average values of PAI-2 in the case 
of tear samples taken four times during PRK: a preoperative 19,8 
ng/ml, in the case of the postoperatively taken samples it was 112,7 
ng/ml, on the postoperative 3
rd
 day 12,1 ng/ml, and on the 
postoperative 5
th
day 15,5 ng/ml. During LASIK, in the case of tear 
samples taken at three occasions, the PAI-2 average values were 
measured as follows: in the case of preoperative samples 19,0 
ng/ml, directly postoperative 111,5 ng/ml and on the postoperative 
first day 15,7 ng/ml.  
We compared the results of PRK and LASIK with two-
sample t-test in the case of preoperative and directly postoperative 
samples. We did not find any significant difference in any of the 
cases (p>0,9, two-sample t-test). Both in the case of PRK and LASIK, 
the postoperative PAI-2 level was significantly higher than the PAI-2 
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level of samples takeŶ at aŶǇ other tiŵe ;p˂0,001 in every case, 
two-sample t-test). We compared the preoperative tear samples 
with samples taken on the 1
st
, 3
rd
 and 5
th
 postoperative days, but 
did not find any significant difference in any of the cases (p>0,1). 
In the case of 40 patients undergoing PRK, we found clear 
cornea during the postoperative three months control period. We 
detected haze (grade 2) in one of the PRK patients during the three 
months. Only one eye of this patient was possible to be involved 
into our study. We detected mild corneal opacification in five more 
eyes undergoing PRK treatment. Out of these patients, we could 
identify one with elevated preoperative PAI-2 level (>2 SD), another 
patient had a high PAI-2 level directly after the laser treatment (>2 
SD). On day 3 and day 5, all eyes in the PRK group with opacification 
had a PAI-2 value within the respective 1 SD of the mean of the PAI-
2 values on those days. In the case of clear cornea none of the 
patients had an elevated preoperative PAI-2 level. However, 3 of 
the eyes had a PAI-2 value beyond 2 SDs on day 3 and another had a 
PAI-2 value beyond 2 SDs on day 5. This PAI-2 value distribution 
beyond the 2 SD level among 146 measurements is to be expected; 
therefore, no significance can be attached to the individual high 
PAI-2 values that were associated with eyes with or without corneal 
opacities. Thus, we could not confirm a significant relationship 
between the preoperatively elevated PAI-2 level and the 
development of corneal haze.  
We found clear cornea at every patient treated with LASIK 
during the follow-up period. However, one eye in the LASIK group 
had a PAI-2 level beyond 2 SDs of the preoperative mean. Another 
eye had a PAI-2 level beyond 2 SDs of the respective mean at day 1. 
This distribution is expected and hence there is no statistical 
significance to this finding. 
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4.2. The change of PAI-1 and PAI-2 value levels in the tear and 
blood samples of pregnant women 
During the examination of healthy pregnant women, there 
was no corneal wounding or injury during the investigation period. 
During pregnancy, the estradiol and progesterone and PAI-2 value 
highly correlated with the pregnant age, and in accordance with the 
literary data their level constantly increased. By contrast, the PAI-2 
level of tear did not correlate with the pregnancy age. The PAI-1 
level in tear samples remained under the detectability limit.  
We compared the PAI-2 levels with the results of the non-
pregŶaŶt patieŶts’ tear saŵples. The aǀerage ǀalues did Ŷot shoǁ 
significant differences in the various periods of pregnancy, except 
for the non-pregnant patieŶts’ results, that ǁas p=0,022 compared 
to the results of 16 weeks pregnant women. 
Between week 8-13 and within the 16
th
 week of pregnancy, 
regarding the PAI-2 level of blood we could not find significant 
differences compared to the values measured within one week 
following child-birth. However, we found a steep increase in the 
PAI-2 levels of blood analysing the average values of 23-26 and 34-
36 weeks pregnant ages. Consequently, the PAI-2 values of blood 
during pregnancy showed significant connection with the pregnant 
age. Notwithstanding the above, the PAI-2 levels of tear did not 
correlate with pregnant age; the values measured in tear samples 
remained constant during pregnancy. 
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5. DISCUSSION 
 
As a summary, we can say that the plasminogen-
activator/inhibitor system plays an important role in numerous 
physiological and pathological processes.  
It seems from previous studies that following the ocular 
surface corneal wounding (e.g. in case of PRK), the PAA decreases or 
either because of the not proper production or the significant 
increase of the PAI-2 level, the cornea heals with opacity, so the 
development of haze can be observed. 
Our study results showed that the measurable amount of 
PAI-1 antigen is missing from the tear before and after the PRK 
treatment, but the PAI-2 level has measurable concentration before 
and after the PRK and LASIK treatments. During LASIK, the PAI-2 
level dropped to the preoperative level already by the first 
postoperative day. We did not have information about the first day 
following the PRK treatment, but on the third day, when we took 
the tear samples, we found the PAI-2 level on a preoperative level. 
We found that the temporal patterns of PRK and LASIK essentially 
match. In the case of PRK and LASIK treatment, the general parallel 
in the temporal pattern of PAI-2 suggests that there is a common 
enzymatic control response in corneal wound healing, even if we 
would believe that wound healing is different in the two processes. 
The uPA activity pattern completes the PAI-2 pattern, 
which was confirmed by previous studies: usually, in normal cases, 
PAI-2 is low when the uPA activity is high, and it is true vice versa. 
They proved that in case the uPA activity is low during the first 
three days after operation it is an accompanying sign of those PRK 
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cases where haze developed. The relationship between low uPA 
activity following PRK and the later developing haze can emerge due 
to the decreased expression of uPA or the higher PAI concentration. 
In our recent study, we measured increased PAI-2 concentration on 
the 3
rd
 and 5
th
 day following PRK and on the 1
st
 day after LASIK in a 
few cases. However, haze did not develop in any of these cases. 
Consequently, based on our results we can say that the decreased 
uPA expression, the non-increasing PAI-2 can be the reason for the 
later developed opacification and haze. 
These observations and the fact that following the 
photorefractive treatment of pregnant rabbits, corneal haze 
developed in them brought us into action to study the change of 
PAI-2 level in blood and tear of human pregnant women as well 
during the pregnancy periods.  The change of the plasminogen 
activator inhibitor level in tear during pregnancy has never been 
studied before. As we could observe in non-pregnant women 
before, the PAI-1 level of tear did not reach the lower level of 
detectability. This state was present during the whole pregnancy 
and also within the first week following child-birth. Therefore we 
believe that the change in PAI-1 level of tear is not significantly 
affected by pregnancy. It was evident that the PAI-2 level of 
pregnant women is not higher than the PAI-2 levels of non-pregnant 
ǁoŵeŶ’s tears. 
We could see the constant increase of the PAI-2 level of 
blood during pregnancy, while the PAI-2 levels measured in tear did 
not correlate with the pregnant age, we could not find any 
significant differences in their level. Thus, it can be concluded that 
the increase of the systematic PAI-2 level measured in blood did not 
lead to a raise in the PAI-2 level of tear. 
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However, we assume that after the wounding of the ocular 
surface, an elevated amount of PAI-2 in blood can get through the 
vessel walls due to the progression of vascular permeability, thus 
increasing the PAI-2 level of tear. We also assume that some kind of 
trigger is necessary for the change of level in the PAI-2 in complex in 
tear, and its release from the complex, e.g. corneal wounding.  
A further increase of the PAI-2 level can occur with its 
release from the complexes found in tears and from the damaged 
epithelial cells of the ocular surface even with normal PAA, which 
can trigger imperfect wound healing. This type of abnormal growth 
of PAIs can lead to corneal wound healing disorders or sometimes 
to the development of corneal ulcer in case of ocular surface 
wounding of pregnant women. 
Determining the PAI leǀels of pregŶaŶt ǁoŵeŶ’s tear 
samples, we can confirm that the PAI values do not increase during 
normal pregnancy in the absence of wounding of surgical 
interventions. In the absence of ocular surface diseases, wounding 
or surgical intervention, the tear levels are independent of the 
change in the blood level of enzymes. This suggests that the 
proteolysis in tears and in the ocular surface might be under local 
control.  On the basis of the above, it can be stated that the 
proteolytic activity of the human organism – including tears – is 
under sensitive regulation, a disturbance in which can lead to 
serious adverse reactions.  
A further analysis of this complex enzymatic system is 
required to perform the incidentally necessary ophthalmological 
interventions with greater security on pregnant patients. 
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6. SUMMARY OF NEW RESULTS  
1. We examined the typical change of plasminogen activator 
inhibitors in tear following the photorefractive laser treatment and 
we found that one eye was detectable with haze by the third month 
following PRK treatments, and further 5 eyes were affected by 
corneal opacification. Out of these patients, one patient was 
measured preoperatively with increased PAI-2 level, and in another 
case; we detected higher PAI-2 level in the directly postoperative 
sample. In the case of PRK treated patients, in whose tear samples 
taken on the postoperative 3
rd
 and 5
th
 days corneal opacification 
was detectable, the average values of PAI-2 were within 1 SD value. 
In the case of PRK patients diagnosed with clear cornea, the 
preoperative PAI-2 average level was not elevated. However, the 
PAI-2 value exceeded the 2 SDs on the 3
rd
 day in the case of three 
eyes, and on the 5
th
 day in another case. In the light of the results 
obtained, we cannot talk about significance in the two cases where 
we observed corneal opacification, when the PAI-2 level was high. 
This way we could not prove a significant connection between the 
preoperative elevated PAI-2 level and the development of corneal 
haze.  
2. We compared the PAI-2 results of PRK and LASIK with the 
help of t-test in the case of preoperative and directly postoperative 
sample. We could not find any significant difference between the 
results PRK and LASIK. During both of these laser treatments there 
was a significant difference between the results taken directly after 
operation and in the other periods. We performed every possible 
combination between the results preoperative and 1
st
, 3
rd
, 5
th
 
postoperative days in tear samples, but could not find significant 
difference in any cases during either of the laser treatments. Based 
on the above results, there can be a common enzymatic control 
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response during the corneal wound healing process in the studied 
refractive surgery procedures even if we thought that the wound 
healing processes differ to a large extent following these two 
procedures. 
3. The PAI-Ϯ leǀels of pregŶaŶt ǁoŵeŶ’s tear saŵples did Ŷot 
correlate with the pregnant age, the values measured in the tear 
samples remained essentially constant during pregnancy. We 
compared the PAI-2 values of tear with the results of non-pregnant 
tear samples. The average values did not differ significantly in the 
various periods of pregnancy , except for comparing the results of 
non-pregnant patients to that of the 16 weeks pregnant women, 
when it was p=0,022. The PAI-1 level in the tear samples remained 
under the lower level of detectability. 
4. Comparing the PAI-2 levels in various pregnant ages, we 
could observe the followings: the values of the 8-13 weeks and the 
16
th
 pregnancy week did not show significant difference compared 
to the 1
st
 week after child-birth. Conversely, a significant difference 
was observable between the average values of the 23-26 and 34-36 
week pregnant ages. The PAI-2 level of blood constantly increased 
with the development of pregnancy. 
In conclusion: the PAI values of pregnant women did not increase 
during normal pregnancy in the absence of wounding of surgical 
interventions. In the absence of ocular surface diseases, wounding 
or surgical intervention, the tear levels are independent of the 
change in the blood level of enzyme. 
Keywords 
plasminogen activator; plasminogen activator inhibitor; excimer 
laser; pregnancy; corneal wound healing 
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